급성 골수성 백혈병 치료 : 시장 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the acute myeloid leukemia therapeutics market size was valued at USD 2.88 billion in 2025 and estimated to grow from USD 3.18 billion in 2026 to reach USD 5.18 billion by 2031, at a CAGR of 10.29% during the forecast period (2026-2031).

This report is Segmented by Therapy Class (Chemotherapy, Targeted Therapy, and More), Mechanism / Molecular Target (FLT3 Inhibitors, IDH1/2 Inhibitors and More), Patient Age Group (Paediatric, Adults and More), Tretament Line(First-Line, Second-Line and More), End User (Hospitals, Specialty Oncology Centres and More) and Geography. The Market Forecasts are Provided in Terms of Value (USD).

Global Acute Myeloid Leukemia Therapeutics Market Trends and Insights

Rising Incidence Of AML Among Ageing Populations

Global life expectancy gains widen the pool of patients over 65 years who are most susceptible to AML. The incidence in this cohort accelerates demand for gentler yet potent regimens, a niche currently filled by venetoclax-based oral combinations that report an overall response rate of 73% in real-world frail cohorts. Outpatient-enabled dosing reduces hospital burden and widens geographic reach, driving a 12.42% CAGR among geriatric patients. National screening policies that encourage baseline bloodwork in seniors further enlarge the diagnosed population.

Precision-Medicine Approvals For FLT3/IDH/BCL-2 Inhibitors

Mutation-specific drugs are rewriting first-line standards. Revumenib became the first menin inhibitor approved for KMT2A-rearranged leukemia, while quizartinib nearly doubled median overall survival in FLT3-ITD-positive disease when paired with backbone chemotherapy. Regulatory confidence in these data spurs companies to broaden label indications and bundle companion diagnostics, resulting in a multiplier effect across therapeutic and testing revenues.

Stringent Multi-Phase Clinical-Trial Attrition

AML's biological diversity demands large, stratified trials that encounter enrollment bottlenecks and soaring costs. Moleculin's MIRACLE study highlights the challenge of recruiting mutation-matched subjects across multiple continents, a hurdle that prolongs timelines and increases costs. Investors price this risk into financing terms, potentially slowing pipeline expansion.

Other drivers and restraints analyzed in the detailed report include:

1. Escalating Global R&D Investments & Venture Financing
2. Expedited FDA/EMA Pathways & Orphan-Drug Incentives
3. Severe Chemo-Toxicity & Treatment-Related Mortality

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Chemotherapy controlled 44.78% of the acute myeloid leukemia therapeutics market in 2025, yet immunotherapy's 12.14% CAGR defines the future revenue slope. Early clinical data on CD371-directed CAR-T cells and CD33-GSPT1 antibody-drug conjugates demonstrate durable remissions in relapsed populations where cytotoxic therapies fail. Stem-cell transplant conditioning also entered the precision era with FDA approval of treosulfan plus fludarabine, a regimen that produces superior long-term survival compared with older busulfan protocols.

Investment inflows sustain this momentum. Bristol Myers Squibb aligns its cell-therapy franchise with antibody conjugates to capture multiple immune pathways, and academic consortia explore dual-antigen CAR designs to bypass antigen-loss relapse. Supportive-care innovations now focus on mitigating cytokine release, thereby broadening eligibility for outpatient administration. The therapy-class mix will therefore shift steadily toward immune-modulating agents that integrate seamlessly with targeted small molecules, expanding the acute myeloid leukemia therapeutics market.

FLT3 inhibitors held 23.21% mechanism-level share in 2025, yet the BCL-2 subclass posts the sharpest 13.22% CAGR, propelled by venetoclax's robust complete-remission depth when combined with hypomethylating agents. Menin inhibition inaugurates a new mechanistic era after revumenib's approval, broadening therapeutic geometry beyond kinase or epigenetic targets.

Pipeline synergies multiply as developers pair BCL-2 blockade with FLT3 or IDH inhibition to forestall clonal escape. Hedgehog and CD33 pathways retain strategic relevance in combination cocktails aimed at minimal residual disease. Consequently, sponsors with diversified target portfolios, rather than single-asset bets, are positioned to capitalize on the projected gains in the acute myeloid leukemia therapeutics market size for the period.

Complete Report Scope:

• By Therapy Class
  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy (incl. CAR-T, bispecifics)
  • Stem-cell Transplant
  • Supportive / Others
• By Mechanism / Molecular Target
  • FLT3 Inhibitors
  • IDH1/2 Inhibitors
  • BCL-2 Inhibitors
  • Hedgehog Pathway Inhibitors
  • CD33-Directed Antibody-Drug Conjugates
• By Patient Age Group
  • Paediatric (<18 yrs)
  • Adults (18-64 yrs)
  • Geriatric (>=65 yrs)
• By Treatment Line
  • First-line
  • Second-line/Relapsed
  • Maintenance
• By End User
  • Hospitals
  • Specialty Oncology Centres
  • Academic & Research Institutes
  • Home/Out-patient Settings
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America captured 43.12% of the acute myeloid leukemia therapeutics market in 2025. The United States drives this dominance through robust private and public reimbursement, widespread mandatory testing, and rapid FDA pathways that reduce the time from submission to bedside. Academic networks such as the Alliance for Clinical Trials link smaller hospitals into nationwide studies, accelerating trial recruitment and broadening early access. Cellular-therapy centers of excellence anchor a thriving referral ecosystem, ensuring continued uptake of high-value interventions. Canada mirrors practice patterns but faces occasional formulary lags. At the same time, Mexico improves access through participation in cross-border clinical trials. Collectively, the region is expected to maintain momentum through 2030, as payer policies increasingly endorse precision approaches that demonstrate superior value.

Europe ranks second by revenue, leveraging centralized EMA approvals to harmonize drug availability. Markets such as Germany and the United Kingdom rapidly integrate newly authorized therapies after rigorous health technology appraisals validate their cost-effectiveness. Recent EMA endorsements of Rytelo and the CRISPR-derived Casgevy illustrate a willingness to back transformative modalities. National genomic strategies fund NGS panels, ensuring that mutation-matched therapies reach eligible patients. Southern European countries adopt at a measured pace due to budget constraints, yet benefit from EU joint procurement initiatives that negotiate volume-based discounts. Overall, Europe's evidence-driven environment sustains stable growth and drives clinical trial diversity, which is essential for mechanistic validation.

Asia-Pacific logs the highest 11.95% CAGR as healthcare infrastructure modernizes and diagnostic capacity expands. Japan's universal coverage rapidly reimburses approved agents, while local studies adapt global regimens to Asian metabolic profiles. China's domestic innovators are leveraging government funding to enter Phase 3 international trials, aiming to match or exceed Western benchmarks in survival rates. India proves the cost-effectiveness of outpatient venetoclax protocols, making precision care viable even in lower-resource settings. Australia and South Korea serve as gateways for clinical trials for multinationals targeting regional approval. The Middle East and Africa remain nascent but show incremental progress through public-private partnerships that build diagnostic labs and negotiate tiered pricing. Together, these trends propel theacute myeloid leukemia therapeutics market into new high-growth territories.

1. Abbvie
2. Amgen
3. Astellas Pharma
4. AstraZeneca
5. Bristol Myers Squibb / Celgene
6. Daiichi Sankyo
7. Roche
8. Genmab
9. Gilead
10. Jazz Pharmaceuticals
11. Johnson & Johnson
12. Novartis
13. Otsuka
14. Pfizer
15. Sanofi
16. Sunesis Pharmaceuticals
17. Syndax Pharmaceuticals
18. Takeda Pharmaceuticals
19. Teva Pharmaceutical Industries
20. Oncolyze

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Incidence Of AML Among Ageing Populations
  • 4.2.2 Precision-Medicine Approvals For FLT3/IDH/BCL-2 Inhibitors
  • 4.2.3 Escalating Global R&D Investments & Venture Financing
  • 4.2.4 Expedited FDA/EMA Pathways & Orphan-Drug Incentives
  • 4.2.5 Outpatient Venetoclax-Based Regimens Expanding Treatable Pool
  • 4.2.6 Wider Adoption Of NGS Companion Diagnostics In Emerging Markets
• 4.3 Market Restraints
  • 4.3.1 Stringent Multi-Phase Clinical-Trial Attrition
  • 4.3.2 Severe Chemo-Toxicity & Treatment-Related Mortality
  • 4.3.3 Cold-Chain/IP Barriers Limiting Novel-Drug Access In Lmics
  • 4.3.4 Rising Cost Burden Of Genomics-Driven Care
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technology Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Bargaining Power of Suppliers
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Threat of New Entrants
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Intensity of Competitive Rivalry

5 Market Size and Growth Forecasts (Value-USD)

• 5.1 By Therapy Class
  • 5.1.1 Chemotherapy
  • 5.1.2 Targeted Therapy
  • 5.1.3 Immunotherapy (incl. CAR-T, bispecifics)
  • 5.1.4 Stem-cell Transplant
  • 5.1.5 Supportive / Others
• 5.2 By Mechanism / Molecular Target
  • 5.2.1 FLT3 Inhibitors
  • 5.2.2 IDH1/2 Inhibitors
  • 5.2.3 BCL-2 Inhibitors
  • 5.2.4 Hedgehog Pathway Inhibitors
  • 5.2.5 CD33-Directed Antibody-Drug Conjugates
• 5.3 By Patient Age Group
  • 5.3.1 Paediatric (<18 yrs)
  • 5.3.2 Adults (18-64 yrs)
  • 5.3.3 Geriatric (>=65 yrs)
• 5.4 By Treatment Line
  • 5.4.1 First-line
  • 5.4.2 Second-line/Relapsed
  • 5.4.3 Maintenance
• 5.5 By End User
  • 5.5.1 Hospitals
  • 5.5.2 Specialty Oncology Centres
  • 5.5.3 Academic & Research Institutes
  • 5.5.4 Home/Out-patient Settings
• 5.6 By Geography
  • 5.6.1 North America
    • 5.6.1.1 United States
    • 5.6.1.2 Canada
    • 5.6.1.3 Mexico
  • 5.6.2 Europe
    • 5.6.2.1 Germany
    • 5.6.2.2 United Kingdom
    • 5.6.2.3 France
    • 5.6.2.4 Italy
    • 5.6.2.5 Spain
    • 5.6.2.6 Rest of Europe
  • 5.6.3 Asia-Pacific
    • 5.6.3.1 China
    • 5.6.3.2 Japan
    • 5.6.3.3 India
    • 5.6.3.4 Australia
    • 5.6.3.5 South Korea
    • 5.6.3.6 Rest of Asia-Pacific
  • 5.6.4 Middle East and Africa
    • 5.6.4.1 GCC
    • 5.6.4.2 South Africa
    • 5.6.4.3 Rest of Middle East and Africa
  • 5.6.5 South America
    • 5.6.5.1 Brazil
    • 5.6.5.2 Argentina
    • 5.6.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products and Services, and Recent Developments)
  • 6.3.1 AbbVie
  • 6.3.2 Amgen
  • 6.3.3 Astellas Pharma
  • 6.3.4 AstraZeneca
  • 6.3.5 Bristol Myers Squibb / Celgene
  • 6.3.6 Daiichi Sankyo
  • 6.3.7 F. Hoffmann-La Roche
  • 6.3.8 Genmab
  • 6.3.9 Gilead
  • 6.3.10 Jazz Pharmaceuticals
  • 6.3.11 Johnson & Johnson (Janssen)
  • 6.3.12 Novartis
  • 6.3.13 Otsuka Holdings
  • 6.3.14 Pfizer
  • 6.3.15 Sanofi
  • 6.3.16 Sunesis Pharmaceuticals
  • 6.3.17 Syndax Pharmaceuticals
  • 6.3.18 Takeda
  • 6.3.19 Teva Pharmaceutical
  • 6.3.20 Oncolyze

7 Market Opportunities and Future Outlook

• 7.1 White-Space and Unmet-Need Assessment